Clinical Trial Search

Primary: Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score — -17.6 units on a scale — p=< 0.001

Primary: Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling — .325; .289; -.418; -.461 Ki-67 labeling index

Primary: Number of Participants With Adverse Events — 99 Participants

Primary: Missing EMR (Electronic Medical Record) Characteristic: Smoking — 9.1; 7.6; 10.7; 7.9 Percentage of participants

Primary: Number of Breast Cancers Detected — 279; 27 cancers detected

Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS 2.2, mCC and NNS — 7.40; 13.08; 8.40; 3.23 ng/mL

Primary: Number of Subjects Reporting Any Solicited Local and General Symptoms — 855; 907; 706; 929 Subjects

Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 83.21; 617.04; 83.57 pg/mg creat — p=<.001

Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350

Primary: Pathologic Complete Response Rate — 7 participants

Primary: Median Progression Free Survival — 7.0 months — p=<0.05

Primary: Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC). — 10 mg — p=0.05

Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 — -4.08; -5.49; -4.92 units on a scale

Primary: Back Pain Change From Baseline at 3 Months — 8.7; 2.7; -6.0 units on a scale

Primary: Number of Subjects Reporting Any Solicited Local Symptoms — 130; 120; 89; 134 Participants